DV
Dividend Vision

MDWD — Mediwound Ltd

Mediwound Ltd (MDWD)

Total return is -88.8% over the past 12.4 years, 499.2 points behind SPY at 410.4%. Its deepest 1-year drawdown was 31.3%.

Mediwound Ltd. is a biopharmaceutical company that develops and commercializes bio-therapeutic solutions for tissue repair and regeneration, including NexoBrid for burn wound treatment, EscharEx for chronic wounds, and MW005 for non-melanoma skin cancers. The company does not currently distribute dividends. Mediwound appeals to growth-oriented investors seeking exposure to specialized therapeutics rather than income-focused investors.

MDWD key facts

Asset type
Stock
Asset class
Equity
Inception date
03/20/2014
Last close
$13.56
Market cap
$183,530,192
Average volume
46700.0
Beta
0.145
Payout ratio
0.0
Forward P/E
34.965
EPS
$-2.21